. Purpose: The most promising attempt to reveal otherwise undetectable autologous blood doping is the Athlete Biological Passport enabling a longitudinal monitoring of hematological measures. Recently, the determination of hemoglobin mass (tHb) was suggested to be incorporated in the adaptive model of the Athlete Biological Passport. The purpose therefore was to evaluate the performance of tHb as part of the adaptive model for the detection of autologous blood transfusions in a longitudinal blinded study. Methods: Twenty-one subjects were divided into a doped group (n = 11) and a control group (n = 10). During the time course of a simulated cycling season (42 wk) including three major competitions (Classics, Grand Tour, World Championships), multiple autologous transfusions of erythrocyte concentrates were assigned in the doped group. A blinded investigator ordered up to 10 tHb measurements (carbon monoxide rebreathing) per subject, mimicking an intelligent doping testing approach in obtaining hematological data (tHb, OFFmass (novel marker including reticulocytes), and respective sequences) for the adaptive model. Results: The final analysis included 199 of 206 overall tHb measurements. The use of tHb, OFFmass, and their sequences as markers of the adaptive model at the 99% specificity level allowed identification of 10 of 11 doped subjects (91% sensitivity) including one false positive in the control group. At the 99.9% specificity level, 8 of 11 subjects were identified without false positives (73% sensitivity). Conclusions: It seems that the problems of tHb determination by carbon monoxide rebreathing limit the application of this method in antidoping. Because of its potential to detect individual abnormalities associated with autologous blood transfusions shown in this study, a method for tHb determination that is compatible with today's standards of testing should be the focus of future research.
T he enhancement of oxygen transfer through blood transfusions was declared a prohibited method by the International Olympic Committee in 1984 and is banned by the World Anti-Doping Agency (WADA) (36) . Whereas homologous blood transfusions can be traced (17, 35) , there is still no unequivocal detection method for autologous blood doping. In this context, the Athlete Biological Passport (ABP) (2, 14, 29, 32, 34) was implemented by WADA (37) to monitor longitudinal biological effects and identify patterns suspicious of various doping techniques, such as blood doping (8) . WADA appointed a hematological module based mainly on hemoglobin concentration ([Hb]), reticulocyte percentage (%ret), the OFF score (OFF-hr) (10) , and various red blood cell indices (37) . Abnormal or suspicious profiles are defined as those that exceed the statistical individual threshold of [Hb] and OFF-hr with a 99% or 99.9% specificity (adaptive model) and are then reviewed by a panel of experts who determine whether the findings are indicative of doping or might be caused by other issues (37) .
Total hemoglobin mass (tHb) is discussed as a new parameter for the detection of autologous blood doping since 2007 (4, 16, 20, 21) and was suggested to be incorporated in the ABP (21) . The rationale behind this is that tHb represents the ultimate target of blood transfusions and, compared with concentration-based variables such as [Hb] and hematocrit (Hct), is independent of plasma volume fluctuations. Furthermore, tHb was found to be relatively stable with a variation of approximately 2%-3% (4, 7, 21) . On the other hand, several physiological and pathological conditions were identified to influence tHb such as altitude exposure, competitions such as cycling stage races, blood donation, or injury (5, 6, 19, 26, 28) . The determination of tHb is nowadays less cumbersome and yields a low analytical error between 1.4% and 2.2 % (7, 9, 16, 19, 21) when the optimized CO rebreathing method is used (25) .
Although many studies discussed the inclusion of tHb in the ABP (4, 7, 13, 16, 20, 21) , so far, only MLrkeberg et al. (16) simultaneously applied autologous blood transfusions and evaluated several passport approaches. In their study, a standardized protocol of tHb determinations was applied before and during 4 wk after retransfusion with the event of blood manipulation always known as a reference point. Because this setting does not resemble real conditions, it remains unclear if the results mirror the detection rates and sensitivities that can be expected in the field.
Therefore, the aim of this study was to assess tHb as a parameter of the adaptive model of the ABP for the detection of autologous blood transfusions in a longitudinal setting of 42 wk using a blinded study design.
METHODS
In this study, tHb was treated as a regular parameter of the adaptive model (32) of the ABP during the simulated time course of a cycling season of 42 wk (Fig. 1) . The unique aspect was that in one of the two study groups, up to four autologous blood transfusions (''doped'') were applied, whereas the other group acted as a control group (''control''). The doped subjects had to be identified in retrospect with an intelligent testing approach where tHb determinations were limited to 10 per subject and ordered by a blinded investigator without knowledge about the group allocation.
Subjects. Twenty-two healthy male volunteers were allocated to the two groups (doped vs control, 11 subjects per group). In doped, the possession of a license in any sports discipline was an exclusion criterion so that no violation of antidoping rules occurred by the study procedures. One subject of control was released from the study after 7 wk because he underwent a regular blood donation. Further exclusion criteria were any clinically relevant bleeding, significant trauma or disease, and hospital admission during the study period. Accordingly, data of 10 control subjects (29 T 5 yr, 182 T 2 cm, 72.8 T 4.0 kg) and 11 doped subjects (28 T 6 yr, 183 T 6 cm, 77.0 T 8.4 kg) were included in the complete study period. In total, 10 subjects (48%) were at least recreationally active cyclists with more than 8 h of training per week. In control, four subjects were regularly engaged in cycling races at the beginning and the end of the observation period unrelated to the theoretical study events described later on. The remaining subjects were regularly participating in various other recreational sports (52%). There was occasional altitude exposure in various heights of up to 7 d in some subjects due to alpine or Nordic skiing in winter. The study was performed in accordance with the latest revised form of the Declaration of Helsinki and approved by the ethics committee of our university. Written informed consent was obtained from all subjects before participation.
Study design. A time frame of 42 wk was chosen to represent the yearly race calendar of a professional cycling season from January to October (Fig. 1) . Accordingly, three competition highlights were defined as potential events to achieve a supraphysiological tHb in doped (Spring Classics in week 13, the Tour de France (TdF) in weeks [28] [29] [30] , and the World Championships in week 38). The subjects of both groups were allocated to either one or two major competitions where, theoretically, their best possible individual performance and thus highest tHb would be expected. Because the seasonal conditions (January to October) could not be met because of time constraints, the study was conducted between July 13, 2009, and May 2, 2010 (42 wk).
To provide the most realistic conditions, two investigators were appointed in separate locations and were blinded to each other's actions throughout the study. The ''principal investigator'' (PI) defined the scheme of autologous blood transfusions beforehand with two to four transfusions of one or two units of autologous erythrocyte concentrates (ECs) per subject on the basis of confessions of doped cyclists. The ECs were used to establish the best possible individual Hb in doped before the designated individual competitions. In two subjects of doped, before the TdF, two units of ECs were transfused simultaneously. After donation, the ECs were reinfused after an interval of 42 T 5 d (range = between 31 and 48 d) because the transfusion law of our country limits the longest possible storage time of autologous ECs to 49 d (11) . An example of the exact removal/infusion schema is depicted along with the adaptively evaluated tHb data in Figure 2 .
On the other hand, the ''doping control investigator'' (DCI) had to gradually schedule up to 10 tHb determinations per subject to reveal autologous blood doping in retrospect.
The DCI was chosen because of his experience in the field of indirect blood doping detection. His ''intelligent'' testing was based on a profound knowledge about the physiological variation of hematologic markers such [Hb] , %ret, OFF-hr, and tHb and their changes induced by blood manipulations as available from various studies (3, 10, 20, 30, 33) . The DCI was informed about the length of the observation period and the time point of the three major competitions (Spring Classics, TdF, World Championships) as well as the virtual competition schedule of each athlete. His thought process required a thorough analysis of the first test results including the classic blood markers ([Hb], %ret, OFF-hr) and estimation of possible time points of blood withdrawal and/or retransfusion integrating the metainformation about the individual competition schedule. He reevaluated the individual blood profiles after each test and was thus able to adopt his further testing strategy. All measurements were conducted as soon as possible after notification by the DCI.
Blood removal and reinfusion. The international standards of transfusion medicine (as adopted by our university's blood bank laboratory) were respected during removal, preparation, and reinfusion of autologous blood (EC). An amount of È500 mL of full blood was removed before EC preparation. The volume of the ECs was È280 mL with an Hct of 53%-60%. Phosphate, adenine, glucose, guanosine, saline, and mannitol were used as storage solution. In selected volunteers (n = 2), apheresis donation (31) was applied once each (MCS+; Haemonetics Corp., Braintree, MA) to simultaneously obtain two ECs per individual. Until reinfusion, the ECs were stored at 4-C in temperature-regulated fridges. .9% specificity). In addition, the percentile at which the sequence falls in the distribution of sequences of the same length assuming there was no doping is indicated below each graph. A, Case of the control group (subject 3). B, Case of the control group with one false-positive strike of tHb between test points 5 and 6 (subject 4). C, Case of the doped group (subject 21); the time points of blood withdrawal and reinfusion are marked by arrows (one arrow per unit; an arrow pointing down indicates withdrawal of 500 mL of full blood; an arrow pointing up, reinfusion of 280 mL of EC).
tHb measurement. The optimized CO rebreathing was used for determination of tHb (25) . Briefly, this method consists of a 2-min rebreathing procedure of a known CO volume (1.0 mLIkg j1 body weight) with a spirometer (Spico-CO-Respirations-Applikator; Universität Bayreuth, Bayreuth, Germany). CO Hb concentration ([COHb] (%)) was measured in capillary samples from the hyperemized earlobe (Finalgon; Boehringer Ingelheim, Ingelheim, Germany) before the start of the test and at minutes 6.5 and 7.5 after CO administration. These blood samples were analyzed using a CO-oximeter (OSM3; Radiometer, Copenhagen, Denmark) and run in at least four replicates each where possible. tHb was calculated from the mean change in %HbCO as described previously (25) .
Duplicate baseline tHb measurements on two consecutive days were performed in 18 of 21 subjects to calculate the typical error (TE) according to Hopkins (12) . These baseline measurements were not communicated to the DCI or included in the adaptive model of the ABP and were performed only to express the analytical error. The TE of 18 duplicate tHb measurements on two consecutive days was 1.5% (95% confidence interval (95% CI) = 1.1%-2.3%).
Great caution was applied to avoid any measurement error, and any test with a leakage or any other possible failure was excluded. In case of an invalid tHb measurement procedure, no repetition was performed to adopt realistic premises.
Hematology and clinical chemistry. Parallel to the tHb determinations, venous blood samples were obtained in accordance with WADA's ABP Operating Guidelines (37) for the determination of hematological data for the adaptive model ([Hb] (gIL j1 ), reticulocytes (%ret) (%), OFF-hr), as described elsewhere (18) . EDTA samples were analyzed only once because it is common practice in clinical laboratories.
Ferritin (KgIL
j1
) was repeatedly measured in doped using enzyme-linked immunosorbent assay technologies (Dade Behring BN ProSpec; Dade Behring, Inc., Deerfield, IL) from a serum sample, and iron was supplemented (ferrous gluconate) on an individual basis when a cutoff ferritin below 20 KgIL j1 was observed. Ferritin results were accessible by the PI only.
Calculations and statistics. In this study, the adaptive model (23, 34) was applied to tHb for calculation of the individual threshold limits (99% or 99.9% specificity levels). The adaptive model is the model recommended in the WADA ABP Operating Guidelines (37). The two-level error model described by Prommer et al. (21) was implemented in the adaptive model. As a parameter of the adaptive model, the analytical uncertainty was set to TE = 1.7%. The within-(WS) and between-subject (BS) variations of biological origin were determined using unbalanced multiway ANOVA after a leave-one-control-out cross-validation procedure. In short, for the application of the adaptive model on the control group, the biological variations were evaluated from all data obtained on nine control subjects (the training set) and then applied on the data obtained on the last 10th subject (the test set). This process was repeated 10 times, once per control subject. For the application of the adaptive model on the doped group, the parameters were obtained from all data obtained on all 10 control subjects. The parameters were the following: WS variance = 814 g 2 and BS variance = 7900 g 2 . The WS variance was further decomposed in an analytical component (assuming a TE = 1.7%) and in a biological component (WS biological variance = 550 g 2 ). The WS variance of biological origin was assumed to be universal; this assumption is discussed later on. A parameter similar to the one presented by MLrkeberg et al. (16) (15) for the evaluation of cancer biomarkers. To evaluate if serial independence can be assumed in the adaptive model, linear increases or decreases in individual sequences of tHb or OFFmass were tested by linear regression with residuals tested for autocorrelation using Durbin-Watson statistics. No trend and no serial correlation was found for all control subjects except for subject 4, who showed a significant increase in both tHb and OFFmass (P G 0.001, see ''Discussion'' section), and for subject 10, who showed an autocorrelated series for OFFmass (U-shaped profile, P = 0.0063).
In addition, the percentile at which the full sequences of tHb and OFFmass fall in the expected distribution of sequences of the same length assuming that there was no doping was derived (33, 34) . The analysis of the full sequence allows detection of not only one single highly abnormal value but also a succession of abnormal values and an abnormally high variance while taking into account random sampling variations.
A ''strike'' was defined as any tHb or OFFmass value exceeding the individual 99% or 99.9% specificity thresholds or a sequence above 99.9%, respectively. Furthermore, as described by other authors (4, 7, 9) , the individual weighted coefficient of variation (CV) (as a TE) was calculated from dividing the individual SD of the consecutive pairwise changes in log-transformed tHb by ¾2, then back transforming. Each estimate of error was then inflated by a factor of 1 + 1/(4 df ) to correct for small-sample bias (9) . The degrees of freedom (df ) were the number of change scores j1.
Where applicable, data are expressed as the mean and SD and/or 95% CI. All calculations were performed either with the JMP statistical software package version 7.0.1 (SAS Institute, Cary, NC) or with MATLAB version 7.7.0 with Statistics Toolbox version 7.0 (MathWorks, Natick, MA).
but two test subjects for whom only eight tests were requested. Applying strict quality measures, seven measurements had to be excluded because of leakage or other measurement errors, so that a total of 199 (96.6%) valid tHb measurements (93 in control, 106 in doped) were included in the final analysis. Using an individual CO dose of 1.0 mLIkg j1 body weight, [COHb] increased from 1.2% T 0.5% before CO administration to 6.3% T 0.8% after CO administration.
The WS and BS variances for tHb and the OFFmass are presented in Table 1 . The use of the adaptive model for tHb and OFFmass allowed identification of doped subjects as displayed in Table 1 (B) and Table 2 (A, B) .
The individual strikes of all individuals are presented in Table 2 (A), whereas the sensitivities, specificities, and positive and negative predictive values of each of the markers are displayed in Table 2 (B). The weighted CV for all tHb measurements in control was 2.8% (95% CI = 1.1%-2.8%) (25 T 11 g during the 10 months) with a range of 1.3%-5.0%, whereas the weighted CV (TE) in doped was 5.2% (95% CI = 4.3%-6.2%) (47 T 13 g during the 10 months) with a range of 2.2%-7.3% (Table 2, C) .
A false-positive strike was only found at the 99% specificity level for one tHb value (subject 4, Fig. 3 ) but not for OFFmass values ( Table 2 ). The sequence analysis of tHb and OFFmass yielded no false-positive strikes (Table 1 and  Table 2 ). Three of 11 subjects in doped did not have any 99.9% strike by any of the four testing measures (tHb, OFFmass, and respective sequences), so that an overall specificity of 100% and a sensitivity of 73% were obtained when applying the current WADA result management protocol (37) . Figure 2 displays an exemplary selection of two subjects of the control group (panels A and B) and one doped subject (panel C). In control subject 4 (panel C), a false-positive strike of tHb was observed at the 99% specificity level in the sixth test but not at the 99.9% level. The time interval between tests 5 and 6 was approximately 4 months, after which an increase of tHb (+86 g) was observed and remained stable in the subsequent tests. This confirms the preliminary analysis performed by linear regression and Durbin-Watson statistics that found a significant increase of tHb over time for subject 4. Figure 3 illustrates the variance of the OFFmass as a function of the variance of tHb.
DISCUSSION
For the first time, tHb was used as a marker of the adaptive model of the ABP in a blinded controlled study design. The main finding is that with 99.9% specificity levels, 8 (73%) of 11 subjects were identified to have values outside of the individual threshold limits in at least one of the four used markers (tHb, OFFmass, and respective sequences), whereas no false-positive strike was observed during a study period of 42 wk. On the first glance, this seems very promising but requires a thorough discussion.
Although several studies discussed the inclusion of tHb in the ABP (4, 7, 13, 16, 20, 21) , so far, only MLrkeberg et al. (16) simultaneously applied autologous blood transfusions and evaluated various passport approaches. Surprisingly, all calculations were made only concerning the retransfusion but not the withdrawal of blood. In our blinded study, the DCI ordered the tests on the basis of the knowledge about the results from previous tests so that it can be assumed that potential time points of blood withdrawal were taken into consideration. To further adopt the best possible realistic conditions, the number of tests was limited to 10.
In the approach of MLrkeberg et al. (16) , where the time point of retransfusion was known and the majority of transfusions included large amounts (three bags of blood in 21 of 29 subjects), during the first 3 d after retransfusion, tHb was the most sensitive marker with È40% of all samples exceeding their 99.9% threshold. In our investigation, after 42 wk using 99% specificity thresholds, tHb had a sensitivity of 82% but yielded the only false-positive strike of study (Fig. 2B,   subject 4) . This subject demonstrated a marked increase in tHb between time points 5 and 6 (+86 g), which were separated by approximately 4 months. Because the subsequent tHb values remained elevated compared with test point 5, we assume that a true natural tHb increase had occurred. In a real-life setting, this profile would have been submitted to a panel of experts who would scrutinize the data and evaluate whether the change is associated with doping or can be attributed to physiological or pathological reasons. Applying the stricter 99.9% specificity threshold, the sensitivity of tHb decreased to 27% but showed no false-positive strikes.
To increase sensitivity, we used %ret to calculate OFFmass where the contribution of %ret to OFFmass was modeled similarly to the contribution to OFF-hr (10) in the ABP (34) . Compared with tHb alone, a better sensitivity of 64% applying 99.9% specificity thresholds was possible for OFFmass and the sequence of OFFmass each, yielding no false-positive strikes ( Table 2 ). Despite our longitudinal blinded study design, these sensitivities also seemed much improved compared with the standardized conditions by MLrkeberg et al. (16) , where optimized sensitivities between 27% to 40% were reported for tHb and Hbmr (a similar marker based on tHb and %ret) after exclusion of two suspicious subjects. This demonstrates that to achieve the best possible sensitivity of the ABP, the timing of testing has to be planned by experts in the field based upon previous results and a profound hematologic knowledge as well as metainformation such as the athlete's whereabouts and competition schedule (''intelligent testing'').
Interestingly, the subject with only two transfusions during the study period remained undetected by any of the markers (Table 2 , subject 14), so it may seem that the sensitivities may be related to the dimension of blood manipulation. On the other hand, during 42 wk, in most doped subjects, only one EC of È280 mL with an Hct of 53%-60% was transfused per time point after a donation of È500 mL of full blood (Table 2 ) so that even these relatively small amounts seem detectable when tHb is used as a marker of the adaptive model.
Our control group provided the reference data for the calculation of the tHb adaptive model as described in the ''Methods'' section. Although the leave-one-out cross-validation procedure presents the advantage to derive sound estimates despite the low number of control subjects, additional studies are nevertheless required to see if the assumption of a universal WS biological variance is tenable. This is a difficult task because any statistics aiming to assess the heterogeneity in the WS variance from the data alone would not allow the separation of biological variations from analytical uncertainty in a straightforward way. It has been shown empirically that an error model that decomposes the WS variance between a biological component given by a universal variance and an analytical uncertainty given by a TE gave the best results (21) , and the same error model was implemented in the adaptive model. The adaptive model is actually able to model individual WS biological variance (stratified prior distribution of WS variance move to individualbased values during data acquisition), but allowing for individual WS biological variance would lead to a significant decrease in sensitivity.
The analytical error of this study expressed as a TE of 1.5% is in line with the values of previous studies in various laboratories where a TE between 1.4% and 2.2% was found (7, 9, 16, 19, 21) , fluctuating around an average value of 1.7% (a TE of 1.7% was used in the calculation of the tHb adaptive model). In addition, we used our control tHb BS variance (7900 g 2 ) and WS biological variance (550 g 2 ), which were larger compared with the data from Prommer et al. (21) (BS variance = 3993 g 2 , WS variance = 408 g 2 ). It was postulated that tHb could be included in the ABP because a low biological variation can be ascertained (5, 21) . In this context, the longitudinal variation of tHb was studied by several groups (applying the optimized CO rebreathing method) and mostly calculated as the weighted CV as described in our ''Methods'' section. Eastwood et al. (4) studied the stability of tHb during 100 d in active men (measurements every 1 to 6 d for 100-114 d) and found a weighted CV of 2.1%. Garvican et al. (7) investigated the seasonal variation of tHb in female road cyclists (the mean number of measurements per athlete was eight during a 6.6 T 2.3-month period) and reported a weighted mean CV of 3.3%. Prommer et al. (21) measured tHb in 24 endurance athletes five times during a year and reported an average oscillation of 4.6%. In comparison with these existing data, we found a similar weighted CV of 2.8% in our control group of 10 subjects, whereas in doped, the weighted CV was 5.2% (Table 2) . Thus, during a long period and under real testing conditions, tHb obtained by the optimized CO method presents with higher variations than in long-term and highfrequency testing regimens. Despite that, the application of the adaptive model to tHb and calculation of OFFmass returns an improved sensitivity to detect autologous blood transfusion compared with previous data. Furthermore, Figure 3 demonstrates that already, the ANOVA of tHb and OFFmass allows a proper discrimination of doped and control subjects. Although four doped subjects seem similar compared to control, the sequence measure of the adaptive model (Table 2 and Fig. 2 ) integrates this observation and takes random sampling variation into account.
Limitations. Under strict and critical appraisal, the sensitivities and specificities may only be valid for the regimen of testing ordered by the DCI of this study and could thus be difficult to extrapolate to others. Because the DCI was a well-trained scientist in the field of indirect blood doping detection, the results may be regarded as optimal. On the other hand, the effects of blood manipulation on erythropoiesis biomarkers are well described in the literature (3, 10, 20, 30, 33) and were acquired by various experts in the field so that it can be speculated that similar decisions regarding the time points of testing would be expected by other DCIs with the same knowledge. Furthermore, it needs to be emphasized that the sensitivities found here merely report the performance of the adaptive model and well-timed tests to reveal autologous blood doping based on analysis of tHb and OFFmass and are not to be equalized with the sensitivity of a positive doping test.
Although this study aimed to have the best possible realistic design, another limitation is the selection of subjects and absence of some real-life confounders of an elite athletic population. Obviously, because of the WADA antidoping regulations, it is impossible to select a group of actively competing elite athletes and expose them to autologous blood transfusion. We tried to include as many recreationally active cyclists in both groups to obtain representative blood samples. The major difference between our group of subjects and an elite population undergoing rigorous training is the fact that hemodilution due to continuous phases of racing (5, 28) and alterations due to possible exposures to altitude of an adequate hypoxic dose are not represented. In this context, it has to be pointed out that in our study, only plasma volume-independent variables are investigated (tHb, %ret); thus, the influence of plasma volume shifts can be negated. The effect of altitude on second-generation blood tests to detect erythropoietin abuse was published by Ashenden et al. (1); data on the effect of altitude on the adaptive model of the ABP do not seem to be available yet. Compared with other longitudinal studies of tHb in active men and even elite athletes (4,7), as described previously, we find a very similar weighted CV in control but a significantly higher weighted CV in doped and thus describe a variation larger than expected with training.
Practical implications. The question remains if these promising results justify or promote the actual inclusion of tHb as a marker of the adaptive model of the ABP. The first answer may be found if our results using tHb are compared with the sensitivities of the current ABP markers [Hb] and OFF-hr, which we studied in the same scenario and published elsewhere (18) . For both levels of specificity (99% and 99.9%), the use of tHb and OFFmass instead of [Hb] and OFF-hr leads to improved sensitivities ( Table 2 in this study  and Table 2 in Pottgiesser et al. [18] ) to detect values outside of individual threshold limits. The same applies for the respective sequence measures. When a combination of all markers is used at the 99% specificity level, tHb and OFFmass showed a sensitivity of 91% compared with a sensitivity of 82% using the classic markers, whereas both sets of markers yielded a false-positive strike (tHb and [Hb]). At the 99.9% specificity level, tHb and OFFmass revealed a sensitivity of 73% and no false-positives compared with a sensitivity of 55% of [Hb] and OFF-hr with a persisting false-positive strike. In other terms, the use of tHb and OFFmass allowed the identification of one additional subject at the 99% specificity level and even two additional subjects at the 99.9% sensitivity level who would have been classified as unsuspicious using solely [Hb] and OFF-hr.
Although this favors tHb and demonstrates its great potential compared with an ordinary venous blood draw, the use of even the optimized CO rebreathing method for determination of tHb is time-consuming and relatively cumbersome and may thus be difficult to implement with larger cohorts of athletes at a competition venue. One further disadvantage of this method is that no quality control system is readily available. We previously discussed that in antidoping, strict analytical protocols and internal as well as external quality controls of forensic standards are of utmost importance to guarantee results that will stand legal scrutiny (27) .
Furthermore, the CO rebreathing method requires subject cooperation and can easily be manipulated by the cheating athlete with a huge effect on the results (e.g., induced CO leakages). It was shown in a recent work that large CO leakages may inflate the mean measurement error up to 9.3% (24), which is not acceptable in an antidoping setting.
Another problematic point is the fact that CO is a potentially toxic substance with a variety of symptoms after exposure to CO that correlate poorly with the level of [COHb] and may show high individual differences (22) . In this context, it seems difficult to oblige healthy athletes to accept the administration of potentially harmful substances for doping control (27) .
CONCLUSIONS AND PERSPECTIVE
It seems that the described risks and problems of tHb determination by CO rebreathing (lacking quality control, CO toxicity, sabotage by athletes) limit the application of this method in antidoping. Because of its potential to detect individual abnormalities associated with autologous blood transfusions shown in this study and the obvious attractiveness of tHb as a plasma volume-independent marker, either a model to infer tHb from easy to measure, yet to be identified blood markers and other (e.g., anthropometrical and activity) data or a method for tHb determination that is compatible with today's standards of testing should be the focus of future research.
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